Pharvaris (NASDAQ:PHVS – Free Report) had its price target decreased by Morgan Stanley from $34.00 to $32.00 in a report published on Tuesday, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock. Separately, Wedbush reduced their price objective on shares of Pharvaris from $27.00 to $24.00 and set an outperform rating for […]
NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Propel Bio Partners invests in companies that improve the quality of life for those with medical conditions, empowering startups with a patient-centric focus for market success.
NorthSea Therapeutics B V : NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
HC Wainwright started coverage on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $44.00 price target on the stock. HC Wainwright also issued estimates for Acelyrin’s Q3 2023 earnings at ($0.29) EPS, Q4 2023 earnings at […]